Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial

Research output: Contribution to journalJournal articlepeer-review

  • Joakim Dillner
  • Susanne K Kjaer
  • Cosette M Wheeler
  • Kristján Sigurdsson
  • Ole-Erik Iversen
  • Mauricio Hernandez-Avila
  • Gonzalo Perez
  • Brown, Peter de Nully
  • Laura A Koutsky
  • Eng Hseon Tay
  • Patricia García
  • Kevin A Ault
  • Suzanne M Garland
  • Sepp Leodolter
  • Sven-Eric Olsson
  • Grace W K Tang
  • Daron G Ferris
  • Jorma Paavonen
  • Matti Lehtinen
  • Marc Steben
  • F Xavier Bosch
  • Elmar A Joura
  • Slawomir Majewski
  • Nubia Muñoz
  • Evan R Myers
  • Luisa L Villa
  • Frank J Taddeo
  • Christine Roberts
  • Amha Tadesse
  • Janine T Bryan
  • Roger Maansson
  • Shuang Lu
  • Scott Vuocolo
  • Teresa M Hesley
  • Eliav Barr
  • Richard Haupt
  • FUTURE I/II Study Group
To evaluate the prophylactic efficacy of the human papillomavirus (HPV) quadrivalent vaccine in preventing low grade cervical, vulvar, and vaginal intraepithelial neoplasias and anogenital warts (condyloma acuminata).
Original languageEnglish
JournalBMJ - British Medical Journal - Clinical Research Edition
Volume341
Pages (from-to)c3493
ISSN0959-8138
Publication statusPublished - 1 Jan 2010

ID: 34127934